Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triheptanoin in Rett Syndrome
NCT02696044Phase 2Unknown
- Sponsor
- Center for Rare Neurological Diseases
- Start
- Jun 2016
- Primary completion
- Feb 2021
- Modality
- SLNs, Nanostructured Lipid Carriers, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of triheptanoin in Rett syndrome (RTT) (6 arms), sponsored by Center for Rare Neurological Diseases. Primary endpoints: Change in Clinical Seizure Frequency at 4 months and Change in Dystonia frequency at 4 months. Status: unknown.
02
Drugs
triheptanoin
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on NCT02696044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02696044.